Amit Joharapurkar
Overview
Explore the profile of Amit Joharapurkar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
235
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patani K, Joharapurkar A, Sundar R, Kshirsagar S, Metiya S, Kumar A, et al.
J Diabetes Complications
. 2025 Feb;
39(3):108977.
PMID: 39987623
Objectives: Type 2 diabetes is caused due to inadequate glucose utilization in the liver and pancreas due to insulin resistance. Glucokinase enzyme plays a key role in metabolism of glucose...
2.
Joharapurkar A, Pandya V, Patel H, Jain M, Desai R
Front Nephrol
. 2024 Nov;
4:1459425.
PMID: 39502472
Desidustat is a small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) discovered and developed by Zydus Lifesciences for the treatment of anemia associated with chronic kidney disease (CKD). This review...
3.
Khatoon S, Das N, Chattopadhyay S, Joharapurkar A, Singh A, Patel V, et al.
Eur J Pharmacol
. 2024 Jul;
978:176800.
PMID: 38950835
Adiponectin plays key roles in energy metabolism and ameliorates inflammation, oxidative stress, and mitochondrial dysfunction via its primary receptors, adiponectin receptors -1 and 2 (AdipoR1 and AdipoR2). Systemic depletion of...
4.
Patel S, Patel S, Kotadiya A, Patel S, Shrimali B, Joshi N, et al.
Lab Anim Res
. 2024 Feb;
40(1):7.
PMID: 38409070
Background: Wistar rats are extensively used as the model for assessing toxicity and efficacy in preclinical research. Hematological and biochemical laboratory data are essential for evaluating specific variations in the...
5.
Patel V, Joharapurkar A, Jain M
Drug Res (Stuttg)
. 2024 Feb;
74(3):113-122.
PMID: 38350634
Hypoxia-inducible factors (HIFs) are transcription factors that are responsible for adapting to the changes in oxygen levels in the cellular environment. HIF activity determines the expression of cellular proteins that...
6.
Patel V, Joharapurkar A, Kshirsagar S, Patel M, Savsani H, Dodiya H, et al.
Toxicol Appl Pharmacol
. 2024 Jan;
483:116832.
PMID: 38266872
Iron deficiency anemia is caused by many pathological conditions like chronic kidney disease (CKD), inflammation, malnutrition and gastrointestinal abnormality. Current treatments that are erythropoiesis stimulating agents (ESAs) and iron supplementation...
7.
Soni R, Delvadia P, Joharapurkar A, Shah J
ACS Chem Neurosci
. 2023 May;
14(11):1935-1949.
PMID: 37227448
Parkinson's disease (PD) is the second most prevailing progressive disorder leading to neurodegeneration, typically in people above 65 years of age. Motor clinical manifestations of PD appear in a much...
8.
Patel V, Joharapurkar A, Jain M
Curr Drug Res Rev
. 2022 Oct;
14(3):215-224.
PMID: 36281831
Diacerein (DCN), an analogue of rhein (a glycosidal compound of natural origin), is currently used in the treatment of osteoarthritis and is given a fast-track designation for development to treat...
9.
Patel V, Joharapurkar A, Kshirsagar S, Patel M, Patel H, Savsani H, et al.
Toxicol Appl Pharmacol
. 2021 Dec;
434:115825.
PMID: 34902352
Dyslipidemia or its severe version like familial hypercholesterolemia causes a high risk for cardiovascular diseases. Lomitapide, a microsomal triglyceride transfer protein inhibitor, is approved to treat familial hypercholesterolemia, associated with...
10.
Chattopadhyay S, Joharapurkar A, Das N, Khatoon S, Kushwaha S, Gurjar A, et al.
Mol Cell Endocrinol
. 2021 Dec;
540:111525.
PMID: 34856343
Adiponectin and insulin resistance creates a vicious cycle that exacerbates type 2 diabetes. Earlier, we observed that female leptin receptor-deficient BLKS mice (BKS-db/db) were more sensitive to an adiponectin mimetic...